neutralizing antibody - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.80 [0.70, 0.91]< 10%1 study (1/-)100.0 %some concernnot evaluable moderatecrucial-
deaths 0.95 [0.51, 1.75]< 143%2 studies (2/-)57.0 %some concernnot evaluable moderatecrucial-
clinical improvement 0.85 [0.56, 1.29]> 10%1 study (1/-)22.3 %lownot evaluable highimportant-
clinical improvement (7-day) 0.85 [0.56, 1.29]> 10%1 study (1/-)22.3 %lownot evaluable highimportant-
death or ventilation 0.83 [0.75, 0.92]< 10%1 study (1/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.10 [0.91, 1.34]> 166%2 studies (2/-)83.3 %some concernnot evaluable moderateimportant-
recovery 1.06 [0.77, 1.46]> 10%1 study (1/-)63.8 %lownot evaluable highnon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %lownot evaluable highimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.